trending Market Intelligence /marketintelligence/en/news-insights/trending/H99FdZo4jgB2qRPoEZNoaQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Precigen's bone marrow cancer drug gets US FDA orphan-drug tag

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Precigen's bone marrow cancer drug gets US FDA orphan-drug tag

Intrexon Corp. said its investigational therapy PRGN-3006 received the U.S. Food and Drug Administration's orphan-drug designation to treat a type of cancer that affects the blood and bone marrow.

PRGN-3006, which was developed using Precigen's Ultracar-T technology, is intended to treat patients with relapsed or refractory acute myeloid leukemia. The company is studying the medicine in an early-stage clinical trial and expects to post an initial data readout in the second half of 2020.

The U.S. FDA grants orphan-drug designation to therapies that can treat, diagnose or prevent rare disorders that affect fewer than 200,000 people in the U.S. Such treatments then receive incentives such as market exclusivity, if approved.

According to the American Cancer Society, about 21,450 new cases of acute myeloid leukemia were expected to be diagnosed in the U.S. in 2019.

Precigen recently changed its name from Intrexon Corp.